ClinicalTrials.gg
Not yet recruitingNCT07951268HEAL-TBUpdated Nov 20, 2026

Health and Economic After-effects in Leicester Tuberculosis Cohort

An observational study in Tuberculosis, sponsored by University of Leicester. Not yet recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University of Leicester · Observational

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 66 studies in Tuberculosis with a site in United Kingdom — 8 open to participants now, 10 under way, none of them phase 3. Tuberculosis · United Kingdom.

Planned enrollment
13th of 20
100 · median 225
Started
2027
the only one that year
Observational
20 of 66
7 open now
Registered
66th of 66
by date

Among the 66 studies in Tuberculosis with a site in United Kingdom, this one is the 13th largest by planned enrollment of the 20 observational ones that give a count, is the only one that started in 2027, is one of 20 observational ones, and was the 66th registered.

Tuberculosis

1,173 studies on the registry are indexed under Tuberculosis; 176 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

8 of the 66 studies in Tuberculosis with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies in Tuberculosis with a site in United Kingdom, or all of them as a file.
02

Study summary

HEAL-TB (Health and Economic After-effects in Leicester Tuberculosis cohort) is a prospective observational study examining recovery among adults with pulmonary and extrapulmonary tuberculosis (TB). The study aims to understand how physical health, mental health, quality of life, daily activity, work and economic wellbeing change during TB treatment and up to 12 months after treatment completion.

Participants may join the study at different stages, from diagnosis until six months after completing TB treatment, and will be followed prospectively until 12 months after treatment completion. The study uses questionnaires, lung function testing, the Incremental Shuttle Walk Test, wrist-worn activity monitoring and information collected during routine clinical care. No experimental treatment is provided and participants continue to receive their usual NHS care.

The study aims to describe recovery over time, compare recovery following pulmonary and extrapulmonary TB, and identify factors associated with persistent health problems or poorer recovery.

Read the detailed description

HEAL-TB is a single-centre prospective observational cohort study designed to characterise physical, psychological and socioeconomic recovery among adults with pulmonary and extrapulmonary tuberculosis. Participants may enter the cohort at different stages of the tuberculosis pathway, from diagnosis or early treatment until six months after treatment completion, and complete the assessments applicable from their point of enrolment onwards. Follow-up continues until 12 months after treatment completion.

The study combines patient-reported outcome measures with objective assessments of physical function and routinely collected clinical information. Outcomes include health-related quality of life, mental health, work productivity and socioeconomic wellbeing, perceived recovery, lung function, functional exercise capacity, physical activity, sedentary behaviour and sleep. Relevant clinical records, imaging reports and routine investigation results are also reviewed to provide information on disease severity, treatment, complications and recovery.

The study is primarily descriptive and exploratory. Recovery trajectories will be characterised over time, with exploratory comparisons between pulmonary and extrapulmonary tuberculosis. Clinical and disease-related characteristics will also be explored as potential predictors of persistent impairment and poorer recovery. The study is intended to improve understanding of recovery beyond treatment completion and inform future approaches to follow-up, rehabilitation and supportive care for people affected by tuberculosis.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Long-term outcomes
  • Cohort study
  • Quality of life
  • Health impacts
  • Post-tuberculosis morbidity
  • Recovery trajectories
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with pulmonary or extrapulmonary tuberculosis receiving care or follow-up through University Hospitals of Leicester NHS Trust. Participants may enter the cohort at different stages of the tuberculosis treatment and recovery pathway, from diagnosis until six months after treatment completion. Participants will be recruited through the UHL clinical tuberculosis service across Leicester Royal Infirmary, Glenfield Hospital and Leicester General Hospital and followed prospectively from enrolment until the applicable final assessment at 12 months after treatment completion.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 16 years or above.
  • Any sex/gender.
  • Pulmonary or extrapulmonary tuberculosis, receiving or having recently completed tuberculosis treatment, with tuberculosis care or follow-up provided through University Hospitals of Leicester NHS Trust. The latest entry point into the cohort is six months after treatment completion.
  • Willing and able to provide to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Expected to move out of the area or unable to attend follow-up visits.
  • Prisoners or people under custodial care.
  • Currently involved in research or recently involved in other research.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • Pulmonary Tuberculosis

    Participants with pulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study.

  • Extrapulmonary Tuberculosis

    Participants with extrapulmonary tuberculosis enrolled in the HEAL-TB observational cohort. Participants will undergo prospective follow-up and study assessments according to the HEAL-TB protocol. No intervention is assigned as part of the study.

06

What researchers measure

Primary outcomes

  1. Health-related quality of life measured by EQ-5D-5L

    Health-related quality of life assessed using the EQ-5D-5L, including the EQ-5D-5L utility index and EQ Visual Analogue Scale (EQ VAS). Repeated measurements will be used to characterise changes in health-related quality of life during tuberculosis treatment and recovery.

    Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion

  2. Depressive symptoms measured by PHQ-9

    Depressive symptoms assessed using the Patient Health Questionnaire-9 (PHQ-9) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery.

    Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion

  3. Anxiety symptoms measured by GAD-7

    Anxiety symptoms assessed using the Generalized Anxiety Disorder-7 (GAD-7) total score. Repeated measurements will be used to characterise mental health trajectories during tuberculosis treatment and recovery.

    Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion

  4. Lung function measured by spirometry

    Pre-bronchodilator spirometry including FEV1, FVC, FEV1/FVC ratio and percent predicted values. Repeated measurements will be used to characterise lung-function trajectories during recovery.

    Time frame: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face

  5. Physical activity measured by wrist-worn activity monitor

    Wrist-worn activity monitoring over 7 days to measure daily physical activity, including steps per day and time spent sedentary and in different physical activity intensity levels.

    Time frame: Study entry and applicable follow-up assessments through 6 months after treatment completion

  6. Work productivity and activity impairment measured by WPAI

    Work Productivity and Activity Impairment questionnaire assessing work time missed, impairment while working, overall work impairment and activity impairment. Repeated measurements will characterise changes in work productivity and activity during treatment and recovery.

    Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion

Secondary outcomes

  1. Functional exercise capacity measured by Incremental Shuttle Walk Test

    Functional exercise capacity assessed using the Incremental Shuttle Walk Test (ISWT), with total distance walked recorded in metres.

    Time frame: Treatment completion, 6 months post-treatment and 12 months post-treatment, where visits are conducted face to face

  2. Respiratory-specific quality of life measured by St George's Respiratory Questionnaire

    Respiratory health status assessed using the St George's Respiratory Questionnaire in participants with pulmonary tuberculosis only, measuring respiratory symptoms, activity limitation and psychosocial impacts.

    Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion

  3. Participant-reported recovery from tuberculosis

    Study-specific questions assessing whether participants consider themselves fully recovered from tuberculosis and how their perceived recovery has changed since the previous study visit.

    Time frame: Study entry and applicable follow-up assessments through 12 months after treatment completion

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — There is currently no plan to make individual participant-level data publicly available. Study findings will be disseminated in aggregate form.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Oct 2028, 21 months later.

Of 123 non-industry observational studies under Tuberculosis, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 21 months is below that.

Counting every sponsor, half of 135 studies reached it within 36 months; a quarter within 21 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Jan 2027
Primary completionEst.
Oct 31, 2028
CompletionEst.
Apr 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951268
Collaborators
Wellcome Trust
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Jan 2027 (estimated)
Primary completion
Oct 31, 2028 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Jake Bodycot
Contact
jb1071@leicester.ac.uk
+447551792221
Manish Pareek
principal investigator · University of Leicester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion